


ISSAR Pharma to license out peptide-based NCEs

06 May 2021 | News

The potential collaboration would help ISSAR Pharmaceuticals in their goal to design and deliver novel peptide-based drugs for various unmet healthcare needs



To boost the production of medicines in these tough times of crisis and to fill the gap in the Indian pharma industry, ISSAR Pharmaceuticals, based in Hyderabad, has decided to license out their peptide-based new chemical entities (NCEs), with pre-IND filing and US Patent.

The potential collaboration would help ISSAR Pharmaceuticals in their goal to design and deliver novel peptide-based drugs for various unmet healthcare needs of the population, and making it affordable and accessible for better health outcomes.

Ramakrishna Reddy Isanaka, Founder and Chairman, ISSAR Pharmaceuticals, sates, “We take pride in being India’s first ever company to conduct Phase-1 clinical trials, and launch the first ever indigenous peptide drug, Melgain in market for the treatment of Vitiligo in 2004.”

ISSAR Pharmaceuticals exclusively focuses on peptide technology-based research and development of new chemical entities (NCE) for various unmet medical needs to improve the quality of life. ISSAR uses Solid-phase peptide synthesis as the technology of choice, and has the capability to synthesise custom peptides, API peptides and cosmetic peptides at all scales within a short duration.

ISSAR’s commitment has also led to the development of their second new chemical entity called Xylentra, which is the first

ever peptide drug in the world for the treatment of burn wounds and microbial infections.

ISSAR developed molecules for prevalent conditions in the western world such as inflammatory bowel diseases (IBD), psoriasis and sepsis. Recently, an NCE for the treatment of burn-wounds (Xylentra) was licensed to Viatris, formerly known as Mylan Laboratories, USA in 2020.